Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Aron Goldhirsch, William C. Wood|Annals of Oncology|2013Cited by 3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Andrew Tutt, Binghe Xu et al.|Annals of Oncology|2015Cited by 1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Marion Procter et al.|The Lancet|2007Cited by 1.5k
Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VIIDiana Crivellari, Marco Bonetti, Monica Castiglione‐Gertsch et al.|Journal of Clinical Oncology|2000Cited by 295
Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast CancerGiuseppe Curigliano, Aron Goldhirsch|Journal of Clinical Oncology|2009Cited by 257